These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21494698)

  • 21. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive pneumococcal disease in Catalonian elderly people, 2002-2009: serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era.
    Vila-Corcoles A; Ochoa-Gondar O; Gomez-Bertomeu F; Raga-Luria X;
    Vaccine; 2011 Oct; 29(43):7430-4. PubMed ID: 21803108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamics and Determinants of Pneumococcal Antibodies Specific against 13 Vaccine Serotypes in the Pre-Vaccination Era.
    Prins-van Ginkel AC; Berbers GA; Grundeken LH; Tcherniaeva I; Wittenberns JI; Elberse K; Mollema L; de Melker HE; Knol MJ
    PLoS One; 2016; 11(1):e0147437. PubMed ID: 26796783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review: current and new generation pneumococcal vaccines.
    Feldman C; Anderson R
    J Infect; 2014 Oct; 69(4):309-25. PubMed ID: 24968238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines.
    Falup-Pecurariu O
    Biomed J; 2012; 35(6):450-6. PubMed ID: 23442357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice.
    Azzari C; Martinón-Torres F; Schmitt HJ; Dagan R
    Pediatr Infect Dis J; 2014 Aug; 33(8):858-64. PubMed ID: 24618937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implication of pneumococcal conjugate vaccines to public health: Thailand perspective.
    Wongsawat J; Chokephaibulkit K
    J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S53-60. PubMed ID: 21294383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 13-valent pneumococcal conjugate vaccine (PCV13).
    Jefferies JM; Macdonald E; Faust SN; Clarke SC
    Hum Vaccin; 2011 Oct; 7(10):1012-8. PubMed ID: 21941097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumococcal vaccines for children: a global public health priority.
    Pittet LF; Posfay-Barbe KM
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():25-36. PubMed ID: 22862432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCVs in individuals at increased risk of pneumococcal disease: a literature review.
    Fletcher MA; Balmer P; Bonnet E; Dartois N
    Expert Rev Vaccines; 2015 Jul; 14(7):975-1030. PubMed ID: 26083459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
    Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
    Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Pneumococcal Conjugate Universal Routine Vaccination on Pneumococcal Disease in Italian Children.
    Fortunato F; Martinelli D; Cappelli MG; Cozza V; Prato R
    J Immunol Res; 2015; 2015():206757. PubMed ID: 26351644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic resistance and the potential impact of pneumococcal conjugate vaccines.
    Dagan R
    Commun Dis Intell Q Rep; 2003; 27 Suppl():S134-42. PubMed ID: 12807290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotypes and pathogens in paediatric pneumonia.
    Hausdorff WP; Dagan R
    Vaccine; 2008 Jun; 26 Suppl 2():B19-23. PubMed ID: 18793602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
    Shibl AM; Memish ZA; Al-Kattan KM
    Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotype-specific problems associated with pneumococcal conjugate vaccination.
    Hanage WP
    Future Microbiol; 2008 Feb; 3(1):23-30. PubMed ID: 18230031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children.
    Esposito S; Principi N
    J Immunol Res; 2015; 2015():591580. PubMed ID: 26351648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough.
    Hausdorff WP; Hoet B; Adegbola RA
    Expert Rev Vaccines; 2015 Mar; 14(3):413-28. PubMed ID: 25266168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.